Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Chembio Diagnostics Inc (CEMI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Chembio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Chembio historical data, for real-time data please try another search
0.455 +0.000    +0.00%
27/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.430 / 0.449
  • Day's Range: 0.447 - 0.455
Chembio 0.455 +0.000 +0.00%

CEMI Balance Sheet

 
Featured here, the Balance Sheet for Chembio Diagnostics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2022
31/12
2022
30/09
2022
30/06
2022
31/03
Total Current Assets 48.45 47.28 40.9 48.22
Cash and Short Term Investments 18.18 21.06 22.84 24.4
Cash - - - -
Cash & Equivalents 18.18 21.06 22.84 24.4
Short Term Investments - - - -
Total Receivables, Net 18.72 5.25 4.26 9.88
Accounts Receivables - Trade, Net 6.54 5.25 4.26 9.88
Total Inventory 7.72 8.47 11.31 11.84
Prepaid Expenses 3.83 12.51 2.5 2.1
Other Current Assets, Total - - - -
Total Assets 62.61 62.18 56.06 62.89
Property/Plant/Equipment, Total - Net 13.72 14.61 14.86 14.3
Property/Plant/Equipment, Total - Gross 26.1 - - 6.05
Accumulated Depreciation, Total -12.38 - - -0.17
Goodwill, Net - - - -
Intangibles, Net - - - -
Long Term Investments - - - -
Note Receivable - Long Term 12.19 - - -
Other Long Term Assets, Total 0.435 0.289 0.297 0.371
Other Assets, Total -11.01 3.21 7.05 1.96
Total Current Liabilities 39.3 38.62 14.03 13.63
Accounts Payable 3.34 3.07 3.78 5.62
Payable/Accrued - - - -
Accrued Expenses 16.39 15.58 6.28 4.92
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 19.57 19.98 3.98 3.09
Other Current liabilities, Total - - - -
Total Liabilities 44.81 44.39 36.15 36.36
Total Long Term Debt 0.087 0.097 16.24 16.99
Long Term Debt 0.01 - 16.13 16.86
Capital Lease Obligations 0.077 0.097 0.116 0.135
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -13.16 -13.33 -13.25 -13.22
Total Equity 17.8 17.79 19.9 26.54
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.368 0.354 0.303 0.303
Additional Paid-In Capital 172.28 171.45 167.04 166.48
Retained Earnings (Accumulated Deficit) -154.3 -153.45 -146.75 -139.8
Treasury Stock - Common -0.207 -0.207 -0.207 -0.207
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -0.337 -0.359 -0.486 -0.244
Total Liabilities & Shareholders' Equity 62.61 62.18 56.06 62.89
Total Common Shares Outstanding 36.72 35.39 30.22 30.22
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CEMI Comments

Write your thoughts about Chembio Diagnostics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Neteli Neteli
Neteli Neteli Dec 30, 2021 6:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Chembio Diagnostics Inc - on December 21, FDA Notified Co That It Was Declining to Review Co's Application for Eua for Dpp Respiratory Antigen Panel. Chembio -fda Notice Said Co Will Need to Collect Influenza a & Influenza B Samples, Submit New Eua Application for Dpp Respiratory Antigen Panel.
Patricia Barros
Patricia Barros Dec 28, 2021 5:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any news?
Faster Hamed
Faster Hamed Nov 29, 2021 9:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Chembio Diagnostics (CEMI) gains 9.5% premarket after receiving South Africa Health Products Regulatory Authority ((SAHPRA)) approval for the DPP SARS-CoV-2 Antigen test,...
Faster Hamed
Faster Hamed Nov 26, 2021 8:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
up up
Faster Hamed
Faster Hamed Nov 15, 2021 9:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HAUPPAUGE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all of the $28.3 million order. Chembio's delivery of tests covered by the purchase order, however, continues to be negatively affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control.
Faster Hamed
Faster Hamed Nov 05, 2021 12:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
But I expect a rapid rise in the near future... I expect to sign an agreement to manufacture Covid devices
Faster Hamed
Faster Hamed Nov 05, 2021 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bad report
World Traveler
World Traveler Nov 03, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2 Major orders in this last Quarter Why is this stock not going up? what am i missing thats not in the news?
Tariq AlZadjali
Tariq AlZadjali Sep 28, 2021 12:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2.59 good to buy in my opinion
Faster Hamed
Faster Hamed Sep 17, 2021 11:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hm hm hm
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email